Trials / Completed
CompletedNCT01179607
Study of Efficacy of a Vasopressin 2 Receptor Antagonist M0002 for Treatment of Ascites in Cirrhotic Subjects With Hypo- or Normonatraemia
A Randomized, Double Blind, Placebo Controlled, Phase II, Dose-titration Trial to Explore the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of M0002 in Cirrhotic Subjects With Ascites and Hypo- or Normonatraemia.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Movetis · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
M0002, an orally active, selective non-peptidergic antagonist of the vasopressin V2 receptor inhibits vasopressin-induced water reabsorption from the kidney. Therefore the aquaretic effect of M0002 has a potential clinical benefit in the treatment of ascites and hyponatreamia in cirrhotic patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | M0002 | |
| DRUG | Placebo |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2010-08-11
- Last updated
- 2010-08-11
Source: ClinicalTrials.gov record NCT01179607. Inclusion in this directory is not an endorsement.